<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>1</volume><submitter>Cui J</submitter><pubmed_abstract>Despite decades of intense global effort, no disease-modifying drugs for Alzheimer's disease have emerged. Molecules targeting catalytic activities of γ-secretase or β-site APP-cleaving enzyme 1 (BACE1) have been beset by undesired side effects. We hypothesized that blocking the interaction between BACE1 and γ-secretase subunit presenilin-1 (PS1) might offer an alternative strategy to selectively suppress Aβ generation. Through high-throughput screening, we discovered that 3-α-akebonoic acid (3AA) interferes with PS1/BACE1 interaction and reduces Aβ production. Structural analogs of 3AA were systematically synthesized and the functional analog XYT472B was identified. Photo-activated crosslinking and biochemical competition assays showed that 3AA and XYT472B bind to PS1, interfere with PS1/</pubmed_abstract><journal>Cell discovery</journal><pagination>15021</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC4860824</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Targeting the γ-/β-secretase interaction reduces β-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis.</pubmed_title><pmcid>PMC4860824</pmcid><pubmed_authors>Li W</pubmed_authors><pubmed_authors>Li X</pubmed_authors><pubmed_authors>Gu H</pubmed_authors><pubmed_authors>Xie X</pubmed_authors><pubmed_authors>Zhang Y</pubmed_authors><pubmed_authors>Cui J</pubmed_authors><pubmed_authors>Nan F</pubmed_authors><pubmed_authors>Wang X</pubmed_authors><pubmed_authors>Zhang C</pubmed_authors><pubmed_authors>Zhao J</pubmed_authors><pubmed_authors>Pei G</pubmed_authors></additional><is_claimable>false</is_claimable><name>Targeting the γ-/β-secretase interaction reduces β-amyloid generation and ameliorates Alzheimer's disease-related pathogenesis.</name><description>Despite decades of intense global effort, no disease-modifying drugs for Alzheimer's disease have emerged. Molecules targeting catalytic activities of γ-secretase or β-site APP-cleaving enzyme 1 (BACE1) have been beset by undesired side effects. We hypothesized that blocking the interaction between BACE1 and γ-secretase subunit presenilin-1 (PS1) might offer an alternative strategy to selectively suppress Aβ generation. Through high-throughput screening, we discovered that 3-α-akebonoic acid (3AA) interferes with PS1/BACE1 interaction and reduces Aβ production. Structural analogs of 3AA were systematically synthesized and the functional analog XYT472B was identified. Photo-activated crosslinking and biochemical competition assays showed that 3AA and XYT472B bind to PS1, interfere with PS1/</description><dates><release>2015-01-01T00:00:00Z</release><publication>2015</publication><modification>2025-04-19T23:19:27.235Z</modification><creation>2019-03-27T02:13:18Z</creation></dates><accession>S-EPMC4860824</accession><cross_references><pubmed>27462420</pubmed><doi>10.1038/celldisc.2015.21</doi></cross_references></HashMap>